Publications

Sullivan AK, Saunders J, Desai M, Cartier A, Mitchell HD, Jaffer S, Ogaz D, Chiavenna C, Charlett A, Diamente V, Golombek R, Manavi K, Priestley C, Waters LJ, Milinkovic A, McOwan A, Estcourt C, Sabin CA, Rodger A, Gold D, Gazzard BG, McCormack S, Gill ON on behalf of the Impact Study Group. 2023.

HIV pre-exposure prophylaxis and its implementation in the PrEP Impact Trial in England: a pragmatic health technology assessment.

Lancet HIV Volume 10, Issue 12, E790-E806, DEC2023 DOI:https://doi.org/10.1016/S2352-3018(23)00256-4

Ogaz D, Cartier A, Mitchell HD, Charlett A, Chiavenna C, Diamente V, Saunders J, Sullivan AK. 2023.

STI incidence and PrEP uptake in participants from underserved populations in the HIV Pre-exposure Prophylaxis (PrEP) Impact trial.

Oral presented at HepHIV 2023.

https://eurotest.org/media/tpkbl3is/as2_06ogaz_hephiv_20231110_final_pub.pdf

Cartier A, Milinkovic A, Pereira B, Reeves I, Ogaz D, Mitchell HD, Saunders J, Charlett A, Chiavenna C, Sullivan AK on behalf of the Impact Study group. 2023.

HIV Seroconversions in the PrEP Impact Trial.

Moderated poster presented at EACS 2023.

https://eacs2023.abstractserver.com/program/#/details/presentations/596

Coukan F, Sullivan A, Mitchell H, Jaffer S, Williams A, Saunders J, Atchison C, Ward H
The increasing equity gaps of pre-exposure prophylaxis (PrEP) access following its commissioning in England – a PrEP-to-need ratio investigation
Sexually Transmitted Infections 2023;99:A10-A11.
https://sti.bmj.com/content/99/Suppl_1/A10.2

Strachan S, Jaffer S, Apea V, Campbell D, Domino J, Davies L, Dugdale J, Nambier K, Onyago D, Ott J, Ross M, Stevenson J, Turner N, Singh G, Sullivan AK. 2021.

Distributing a questionnaire for women attending a Sexual Health Clinic increases PrEP uptake.

Oral presented at HepHIV Conference 2021.

https://region-hovedstaden-ekstern.23video.com/po4-7-strachanmp4mp4

Sullivan A, Chiavenna C, Cartier A, Jaffer S, Mitchell HD, Ogaz D, Mason E, Osman R, Coukan F, Diamente V, Golombek R, Richardson D, Strachan S, Manavi K, McCormack S, Priestley C, Waters LJ, Estcourt C, Gold D, Goldberg D, Peto T, Rodger A, Sabin C, Charlett A, Desai M, Saunders J, Gill ON, on behalf of the Impact Study Group. 2021.

HIV and STI incidence among MSM users and non-users of HIV PrEP in England: results from the Impact trial.

Moderated poster presented at EACS 2021.

https://eacs2021.abstractserver.com/program/#/details/presentations/381

Summary by Gus Cairns for NAM-aidsmap https://www.aidsmap.com/news/oct-2021/first-efficacy-results-englands-prep-impact-trial

Hibbert M, Osman R, Suchak T, Ross M, Mason E, Enayat Q, Mitchell HD, Chiavenna C, Nambiar K, Cartier, A, Jaffer S, Diamente V, Saunders J, Sullivan AK, on behalf of the Impact Study Group. 2021.

PrEP Impact trial participation among trans and non-binary sexual health attendees in England.

Moderated poster presented at EACS 2021.

https://eacs2021.abstractserver.com/program/#/details/presentations/213

Chiavenna C, Mitchell HD, Osman R, Mason E, Hibbert M, Enayat Q, Cartier A, Jaffer S, Diamente V, Golombek R, Estcourt C, Sabin C, Saunders J, Charlett A, Sullivan AK. 2021.

STI Incidence among participants in the HIV Pre-exposure Prophylaxis (PrEP) Impact trial in England.

Oral presented at IAS Conference 2021.

https://theprogramme.ias2021.org/Abstract/Abstract/2106

Sullivan AK, Saunders J, Cartier A, Jaffer S, Milinkovic A, Priestly C, Manavi K, Waters LJ, Mason E, Hibbert M, Chiavenna C, Charlet A, Escourt C, Sabin C, Rodger A, Gold D, McOwan A, Gil N, Desai M, Impact Study Group.

Baseline demographics, coverage and first regimen choice of participants in the HIV Pre-Exposure Prophylaxis (PrEP) Impact trial.

Poster presented at HIV4RP Conference 2021.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894025/ [see abstract PE16.35LB]

Cartier A, Jaffer S, Diamente V, Foster D, Golombek R, Chhibbar P, Estcourt C, Sabin C, Rogers A, Sullivan AK. 2021.

The PrEP Impact Trial – experience in setting up Independent Provider sites.

Poster presented at BASHH/BHIVA Joint Conference 2021.

https://www.bhiva.org/file/6091178219915/AbstractBook2021.pdf [see abstract P175]

Mason E, Osman R, Hibbert M, Enayat Q, Mitchell HD, Chiavenna C, Saunders J, Sullivan AK, Chhibbar P, Golombek R, McCormack S, Desai M, Manavi K. 2021.

Distance travelled to access pre-exposure prophylaxis (PrEP) for HIV prevention on the PrEP Impact trial in England during 2017-2020.

Poster presented at BASHH/BHIVA Joint Conference 2021.

https://www.bhiva.org/file/6091178219915/AbstractBook2021.pdf [see abstract P079]

Strachan S, Jaffer S, Apea V, Campbell D, Domino J, Davies L, Dugdate J, Nambier K, Onyago D, Otti J, Ross M, Stevenson J, Turner N, Singh G, Sullivan AK. 2021.

Distributing a questionnaire for women attending a Sexual Health Clinic increases PrEP uptake.

Poster presented at BASHH/BHIVA Joint Conference 2021.

https://www.bhiva.org/file/6091178219915/AbstractBook2021.pdf [see abstract P074]

The HIV pre-exposure prophylaxis (PrEP) Impact trial: baseline demographics, coverage and first regimen choice.

Oral presented at BASHH/BHIVA Joint Conference 2021.

https://www.bhiva.org/AnnualConference2021Presentations / https://vimeo.com/557145391

Summary by Gus Cairns for NAM-aidsmap https://www.aidsmap.com/news/apr-2021/englands-big-prep-implementation-trial-releases-its-enrolment-data-young-people-under

Other Material

Women and PrEP

PrEP awareness videos co-designed with the Women and other Groups subcommittee of the PrEP Impact trial’s Community Advisory Board

https://www.womenandprep.org.uk/

Routine commissioning of HIV pre- exposure prophylaxis (PrEP) in England

Monitoring and evaluation framework version 1 March 2022

https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1059310/UKHSA-PrEP-monitoring-and-evaluation-framework-for-England-2022.pdf

DHSC message on commissioning following the end of the PrEP Impact Trial, March 2020

https://www.gov.uk/government/news/hiv-drug-prep-to-be-available-across-england